Deccan Health Care Ltd

Deccan Health Care, a microcap pharmaceutical company, reported flat performance for the quarter ending September 2024 with a score of -2. However, net sales were the highest in the last five quarters at Rs 18.82 crore and sales trend is positive. Operating cash flow for the year was the lowest in three years at Rs -12.55 crore. Investors should carefully evaluate the company's financials before making any investment decisions.

Deccan Health Care, a microcap pharmaceutical company, has reported a flat performance for the quarter ending June 2024, with a score of 1 out of 10. However, the company's Profit After Tax has shown a strong growth, while net sales have decreased by 11.7%. Investors should carefully evaluate all factors before investing.

Deccan Health Care, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO after reporting a 27.74% growth in net sales and higher PAT in March 2024. While technical indicators suggest a bullish trend, the company has weak long-term fundamentals and is trading at a premium. Majority shareholders are non-institutional investors.

Deccan Health Care, a microcap pharmaceutical company, has reported positive financial results for the quarter ended March 2024, with a 27.74% increase in net sales and higher profit after tax. However, the company's operating profit and margin have decreased, indicating room for improvement. Investors are advised to carefully evaluate the company's financials before investing.

Deccan Health Care, a microcap pharmaceutical company, has hit a 52-week low on May 30, 2024. MarketsMOJO has given the stock a 'Strong Sell' rating, indicating a negative outlook. The stock has been highly volatile and is currently trading below its moving averages, with a -34.18% 1-year performance compared to Sensex's 17.73%.

Deccan Health Care, a microcap pharmaceutical company, has hit a 52-week low in its stock price on May 22, 2024, dropping to Rs. 21.3. This decline has been reflected in the stock call given by MarketsMOJO, labeling it as a Strong Sell. The company's stock has underperformed the sector and is currently trading below its moving averages. Its 1-year performance has been -32.85%, indicating a lack of market trend alignment. Investors are advised to conduct their own research before making any investment decisions.

Deccan Health Care, a microcap pharmaceutical company, has hit a 52-week low and received a 'Strong Sell' rating from MarketsMOJO. The stock has shown high volatility, trading below its moving averages and underperforming the sector. In the past year, its stock performance has been negative, highlighting the company's struggles in the market.

Deccan Health Care, a microcap pharmaceutical company, has recently hit a 52-week low in its stock price of Rs.22.9. This has led to a 'Strong Sell' call by MarketsMOJO. The company's stock has underperformed the sector by -4.95% and is currently trading below its moving averages, indicating a downward trend. In the past year, the stock has shown a negative performance of -20.14%, highlighting its underperformance in the market.

Deccan Health Care, a microcap pharmaceutical company, has reported a positive performance in the quarter ending December 2023. The company's net sales have grown by 59.30% year on year, while its operating profit and profit before tax have also shown a positive trend. MarketsMOJO has given a 'Strong Sell' call for the company's stock based on these results.